CD4 + CD25high Regulatory T Cell Numbers and FOXP3 mRNA Expression in Patients with Advanced Esophageal Cancer Before and After Chemotherapy

Cell Biochemistry and Biophysics

Volumn 61, Issue 2, 2011, Pages 389-392

  Xu, Tengyun ^a   Duan, Qiaohong ^a   Wang, Gang ^a   Hu, Bing ^a  

^a ANHUI PROVINCIAL HOSPITAL   (China)

Author keywords

Advanced esophageal cancer; CD4 + CD25high regulatory T cells; FOXP3

Indexed keywords

ANTINEOPLASTIC AGENT; FORKHEAD TRANSCRIPTION FACTOR; FOXP3 PROTEIN, HUMAN; INTERLEUKIN 2 RECEPTOR ALPHA; MESSENGER RNA;

ADULT; AGED; ARTICLE; CANCER STAGING; CELL COUNT; CYTOLOGY; DRUG EFFECT; ESOPHAGUS TUMOR; FEMALE; GENE EXPRESSION REGULATION; GENETICS; HUMAN; IMMUNOLOGY; MALE; METABOLISM; MIDDLE AGED; PATHOLOGY; REGULATORY T LYMPHOCYTE;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; CELL COUNT; ESOPHAGEAL NEOPLASMS; FEMALE; FORKHEAD TRANSCRIPTION FACTORS; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; INTERLEUKIN-2 RECEPTOR ALPHA SUBUNIT; MALE; MIDDLE AGED; NEOPLASM STAGING; RNA, MESSENGER; T-LYMPHOCYTES, REGULATORY;

EID: 80955137468     PISSN: 10859195     EISSN: None     Source Type: Journal    
DOI: 10.1007/s12013-011-9197-1     Document Type: Article

References (13)

1. Paust, S., & Cantor, H. (2005). Regulatory T cells and autoimmune disease. Immunological Review, 204, 195-207.
2. Takahashi, T., & Sakaguchi, S. (2003). The role of regulatory T cells in controlling immunologic self-tolerance. International Review of Cytology, 225, 1-32.
3. Terabe, M., & Berzofsky, J. A. (2004). Immunoregulatory T cells in tumor immunity. Current Opinion in Immunology, 16, 157-162.
4. Wolf, A. M., Wolf, D., Steurer, M., Gastl, G., Gunsilius, E., & Grubeck-Loebenstein, B. (2003). Increase of regulatory T cells in the peripheral blood of cancer patients. Clinical Cancer Research, 9, 606-612.
5. Hori, S., Nomura, T., & Sakaguchi, S. (2003). Control of regulatory T cell development by the transcription factor Foxp3. Science, 299, 1057-1061.
6. Sakaguchi, S., & Powrie, F. (2007). Emerging challenges in regulatory T cell function and biology. Science, 317, 627-629.
7. Lopes, J. E., Soper, D. M., & Ziegler, S. F. (2007). Foxp3 is required throughout the life of a regulatory T cell. Science STKE, 393, pe36.
8. Sasada, T., Kimura, M., Yoshida, Y., Kanai, M., & Takabayashi, A. (2003). CD4 + CD25 + regulatory T cells in patients with gastrointestinal malignancies: possible involvement of regulatory T cells in disease progression. Cancer, 98, 1089-1099.
9. Needham, D. J., Lee, J. X., & Bailharz, M. W. (2006). Intra-tumoral regulatory T cells: a potential new target in cancer immunotherapy. Biochemical and Biophysical Research Communications, 343, 684-691.
10. Okita, R., Saeki, T., Takashima, S., Yamaguchi, Y., & Toge, T. (2005). CD4 + CD25 + regulatory T cells in the peripheral blood of patients with breast cancer and non-small cell lung cancer. Oncological Report, 14, 1269-1273.
11. Ichihara, F., Kono, K., Takahashi, A., Kawaida, H., Sugai, H., & Fujii, H. (2003). Increased populations of regulatory T cells in peripheral blood and tumor-infiltrating lymphocytes in patients with gastric and esophageal cancers. Clinical Cancer Research, 9, 4404-4408.
12. Zhang, L., Dermawan, K. T., Jin, M. L., Xiong, S. D., & Chu, Y. W. (2008). Does chemotherapy augment anti-tumor immunotherapy by preferential impairment of regulatory T cells? Medical Hypotheses, 71, 802-804.
13. Martin, B., Banz, A., Bienvenu, B., et al. (2004). Suppression of CD4 + T lymphocyte effector functions by CD4 + CD25 + cells in vivo. The Journal of Immunology, 172, 3391-3398.